Dental complications due to the use of bisphosphonates
DOI:
https://doi.org/10.59471/ijhsc2024107Keywords:
Bisphosphonates, antiresorptive therapy, osteonecrosis of the jaw, dental complicationsAbstract
Objective: The main objective of this article is to describe dental complications due to the use of bisphosphonates through a bibliographic review. In turn, this objective had the following specific objectives: a) Identify the treatments in patients administered bisphosphonates, and b) Know the types of bisphosphonates most used associated with dental complications. Materials and methods: This research uses a qualitative approach, which developing through documentary-type research to describe the points raised in the objectives. A systematic review carrying out applying the PRISMA methodology, where the Scopus and PubMed databases using to search for the information in documents published between January 1, 2018 and January 31, 2023 to select the appropriate ones according to inclusion and exclusion criteria. Results: From 11897 initially identified articles, only nine articles met all the eligibility criteria for this study. The selected articles are of high impact belonging to journals within quartiles 1 and 2. Among the most outstanding findings is that the use of antiresorptive therapies with bisphosphonates cause dental complications such as osteonecrosis of the jaw and risks in cases of dental extractions. In addition, the most widely used type of bisphosphonate is zoledronate, the major cause of osteonecrosis of the jaw. Conclusions: Antiresorptive therapies with the use of bisphosphonates, especially with the administration of zoledronate, are the main causes of osteonecrosis of the jaw
References
Sedghizadeh PP, Sun S, Jones AC, Sodagar E, Cherian P, Chen C, et al. Bisphosphonates in dentistry: Historical perspectives, adverse effects, and novel applications. Bone [Internet]. el 1 de junio de 2021 [citado el 12 de diciembre de 2022];147:1–24. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33757899/
Koide Y, Kataoka Y, Hasegawa T, Ota E, Noma H. Effect of systemic bisphosphonate administration on patients with periodontal disease: a systematic review and meta-analysis protocol. BMJ Open. el 4 de marzo de 2022;12(3):e057768.
Nieckula P, Stempniewicz A, Tubaja M. Prophylaxis of osteonecrosis in the case of patients treated with bisphosphonates: A review paper. Dent Med Probl [Internet]. el 1 de octubre de 2018 [citado el 12 de diciembre de 2022];55(4):425–9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30521152/
Alrahabi MK, Ghabbani HM. Clinical impact of bisphosphonates in root canal therapy. Saudi Med J [Internet]. el 1 de marzo de 2018 [citado el 12 de diciembre de 2022];39(3):232–8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29543299/
de-Freitas NR, Lima LB, de-Moura MB, Veloso-Guedes C do CF, Simamoto- Júnior PC, de-Magalhães D. Bisphosphonate treatment and dental implants: A systematic review. Med Oral Patol Oral Cir Bucal [Internet]. el 1 de septiembre de 2016 [citado el 29 de enero de 2023];21(5):e644. Disponible en:
/pmc/articles/PMC5005105/
Daron C, Deschaumes C, Soubrier M, Mathieu S. Viewpoints of dentists on the use of bisphosphonates in rheumatology patients. Int Dent J [Internet]. el 1 de agosto de 2018 [citado el 12 de diciembre de 2022];68(4):279–86. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29446061/
Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons’ Position Paper on
Medication-Related Osteonecrosis of the Jaws—2022 Update. Journal of Oral and Maxillofacial Surgery. el 1 de mayo de 2022;80(5):920–43.
Fiorillo L, Cicciù M, Tözüm TF, D’Amico C, Oteri G, Cervino G. Impact of bisphosphonate drugs on dental implant healing and peri-implant hard and soft tissues: a systematic review. BMC Oral Health. el 17 de diciembre de 2022;22(1):291–303.
Mustafa Gomes Muniz FW, da Silva BF, Goulart CR, da Silveira TM, Martins TM. Effect of adjuvant bisphosphonates on treatment of periodontitis: Systematic review with meta-analyses. J Oral Biol Craniofac Res. abril de 2021;11(2):158–68.
Helmi M, Alosaimy S, Goodson JM, Hasturk H, Natto ZS. Annual alveolar bone loss in older adults taking oral bisphosphonate: a retrospective cohort study. BMC Oral Health [Internet]. el 27 de noviembre de 2019 [citado el 13 de diciembre de 2022];19(1):260. Disponible en: /pmc/articles/PMC6881984/
Linares-Espinós E, Hernández V, Domínguez-Escrig JL, Fernández-Pello S, Hevia V, Mayor J, et al. Metodología de una revisión sistemática. Actas Urol Esp. el 1 de octubre de 2018;42(8):499–506.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol. el 1 de junio de 2021;134:103–12.
Hadaya D, Soundia A, Freymiller E, Grogan T, Elashoff D, Tetradis S, et al. Nonsurgical Management of Medication-Related Osteonecrosis of the Jaws Using Local Wound Care. Journal of Oral and Maxillofacial Surgery [Internet]. noviembre de 2018 [citado el 29 de enero de 2023];76(11):2332–9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29932939/
Kizub DA, Miao J, Schubert MM, Paterson AHG, Clemons M, Dees EC, et al. Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). Supportive Care in Cancer [Internet]. el 15 de mayo de
[citado el 29 de enero de 2023];29(5):2509–17. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32929540/
Zhou Y, Yu Y, Shi Y, Li M, Yang C, Wang S. Combined Administration of Bisphosphonates, Chemotherapeutic Agents, and/or Targeted Drugs Increases the Risk for Stage 3 Medication-Related Osteonecrosis of the Jaw: A 4-Year Retrospective Study. Biomed Res Int [Internet]. el 15 de octubre de 2020 [citado el 29 de enero de 2023];2020:1–9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/33123580/
Bulsara VM, Bulsara MK, Lewis E. Protocol for prospective randomised assessor-blinded pilot study comparing hyperbaric oxygen therapy with PENtoxifylline+TOcopherol± CLOdronate for the management of early osteoradionecrosis of the mandible. BMJ Open [Internet]. el 4 de marzo de 2019 [citado el 29 de enero de 2023];9(3):e026662. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30837258/
Wick A, Bankosegger P, Otto S, Hohlweg-Majert B, Steiner T, Probst F, et al. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Clin Oral Investig [Internet]. el 23 de marzo de 2022 [citado el 29 de enero de 2023];26(3):2839–52. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34812959/
Ottesen C, Schiodt M, Jensen SS, Kofod T, Gotfredsen K. Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: a randomized clinical feasibility trial of drug holiday versus drug continuation. Oral Surg Oral Med Oral Pathol Oral Radiol [Internet]. febrero de 2022 [citado el 29 de enero de 2023];133(2):165–73. Disponible en: https://pubmed.ncbi.nlm.nih.gov/34275774/
Kaneko J, Okinaga T, Hikiji H, Ariyoshi W, Yoshiga D, Habu M, et al. Zoledronic acid exacerbates inflammation through M1 macrophage polarization. Inflamm Regen [Internet]. el 23 de diciembre de 2018 [citado el 29 de enero de 2023];38(1):16. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29977413/
Hajeri S, Alturkistany Y. Medication-related osteonecrosis of the jaw after dental clearance: Prevalence in an oncology center. Saudi Dent J [Internet]. septiembre de 2022 [citado el 29 de enero de 2023];34(6):479–84. Disponible en: https://www.sciencedirect.com/science/article/pii/S101390522200075X
Ristow O, Rückschloß T, Moratin J, Müller M, Kühle R, Dominik H, et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake—A randomized pilot trial. Oral Dis [Internet]. el 10 de abril de 2021 [citado el 29 de enero de 2023];27(3):532–46. Disponible en: Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake—A randomized pilot trial
Published
Issue
Section
License
Copyright (c) 2024 Miranda Rosero Oswaldo Damian, Paredes Herrera Maria Eugenia, Josselyn Eliss Miranda Fernandez, Pujos Pérez Julio César (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
How to Cite
